The €80 million Series B establishes a European leader in Radiopharmaceuticals

Europe has a long history of radiopharmaceutical drug development expertise. The Advanced Accelerator Applications (AAA) in France were a pioneer in the field. In 2018, AAA (now part of Novartis) launched one of the most well-known radiopharmaceutical drugs, Lutathera, for…